![]() Drug formularies are widely used by hospitals, health systems, and private and national drug insurance plans.Provenance: Not commissioned externally peer reviewed. (related to preventing drug name confusions) Other: Board of Directors (unpaid) for Med-Errs, Inc. Grants received: Abbott (readability of MedGuides), Novartis (development of pharmacoepidemiologic methods), Ortho McNeil (safety of warfarin post orthopedic surgery), AHRQ (Tools for Optimizing Prescribing). (my own company, specializing in preventing and detecting drug name confusion errors). BL consulted in last 3 years: Abbott (drug name confusion), Transcept. DT received unrestricted grant funding for research from Medco Health Solutions. MK is a Consultant Pharmacist, Pharmacy and Therapeutics Committee, Catalyst Health Solutions, Inc, Rockville, MD. SW consulted for Abbott, Genentech, Primus. JD had a summer student internship with Abbott Laboratories in Regulatory Affairs 2009–2010 7 k (2009) 8 k (2010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: WG received grant funding from Abbott Labs- 2% FTE this year, Consulting with Walgreens (member of P&T Committee, ∼$5,000). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.įunding: This work originated from the Formulary Leveraged Improved Prescribing (FLIP) project, which was funded by the Attorney General Consumer and Prescriber Education Grant Program, and was supported by the Agency for Healthcare Research and Quality grant U18HS016973 funding the UIC Center for Education and Research on Therapeutics (CERT) program. PLoS Med 9(5):Ĭopyright: © 2012 Schiff et al. (2012) A Prescription for Improving Drug Formulary Decision Making. US payers were then asked specific questions about each section of the AMCP dossier.Citation: Schiff GD, Galanter WL, Duhig J, Koronkowski MJ, Lodolce AE, Pontikes P, et al. US payers were asked to rate the usefulness of each section of the AMCP dossier on a scale of 0 to 10, where 0 is not useful at all and 10 is extremely useful. Interviews focused on how AMCP dossiers inform decision making and the usefulness of each dossier section. Participants included 7 medical directors and 3 pharmacy directors who were voting members or chairs of Pharmacy and Therapeutics (P&T) committees at a range of US health plans (national, regional, integrated) (Table 1). We then developed a discussion guide for use in one-on-one interviews. To characterize decision makers’ use of AMCP dossiers in granting reimbursement and formulary placement for new health technologies, we reviewed the published literature and third-party websites to identify how health care decision makers employ AMCP dossiers. Limited information has been published on the role of these dossiers in health care decision making. The dossier format guides manufacturers in presenting evidence for new pharmaceuticals, biologics, and vaccines to gain reimbursement and/or formulary placement in the United States (US) health care system. The Academy of Managed Care Pharmacy (AMCP) dossier format was introduced in 2000.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |